Literature DB >> 19748721

[Lung cancer and COPD: a common combination].

José Abal Arca1, Isaura Parente Lamelas, Raquel Almazán Ortega, José Blanco Pérez, María Elena Toubes Navarro, Pedro Marcos Velázquez.   

Abstract

BACKGROUND AND
OBJECTIVE: To analyse frequency, characteristics and patient survival with lung cancer (LC) and COPD, comparing them with patients without COPD.
MATERIAL AND METHODS: A retrospective study, of patients diagnosed by means of cytohistology. Survival was estimated by the Kaplan-Meier method. The statistical analysis was carried out using SPSS 15.0.
RESULTS: A total of 996 patients were diagnosed, 39.8% COPD. Mean age 70+/-9.19 years. GOLD stages: I 18.2%, II 53.6%, III 24%, IV 4.2%. The histological types: squamous cell carcinoma 48.2%, adenocarcinoma 22%, small cell carcinoma 22.5%. Survival was longer in the COPD group.
CONCLUSIONS: LC and COPD are combined in 39.8%. Squamous cell type is more frequent and survival was longer in the COPD group.

Entities:  

Mesh:

Year:  2009        PMID: 19748721     DOI: 10.1016/j.arbres.2009.07.005

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  10 in total

1.  Lung cancer and chronic obstructive pulmonary disease: understanding the complexity of carcinogenesis.

Authors:  Cecilia Mouronte-Roibás; Alberto Ruano-Raviña; Alberto Fernández-Villar
Journal:  Transl Lung Cancer Res       Date:  2018-09

2.  Features of the Metabolic Profile of Saliva in Lung Cancer and COPD: The Effect of Smoking Status.

Authors:  Lyudmila V Bel'skaya; Elena A Sarf; Denis V Solomatin; Victor K Kosenok
Journal:  Metabolites       Date:  2021-04-30

3.  Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors.

Authors:  José Luis Izquierdo; Pilar Resano; Abdulkader El Hachem; Desiré Graziani; Carlos Almonacid; Ignacio M Sánchez
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-09-30

4.  Effect of COPD on Inflammation, Lymphoid Functions and Progression-Free Survival during First-Line Chemotherapy in Advanced Non-small Cell Lung Cancer.

Authors:  Márton Szentkereszty; Zsolt István Komlósi; Gergő Szűcs; Gábor Barna; Lilla Tamási; György Losonczy; Gabriella Gálffy
Journal:  Pathol Oncol Res       Date:  2019-05-14       Impact factor: 3.201

5.  [Comparative analysis of clinical features of lung cancer in west China hospital in 2000 and 2010].

Authors:  Xiaojun Yao; Lunxu Liu; Hongwei Zhnag; Qiang Pu; Hu Liao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-06

6.  Does chronic obstructive pulmonary disease relate to poor prognosis in patients with lung cancer?: A meta-analysis.

Authors:  Hefeng Lin; Yunlong Lu; Liya Lin; Ke Meng; Junqiang Fan
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

7.  [Smoking intervention in patients with cardiovascular diseases].

Authors:  José Ignacio de Granda-Orive; Segismundo Solano-Reina; Carlos Andrés Jiménez-Ruiz
Journal:  Aten Primaria       Date:  2012-03-10       Impact factor: 1.137

8.  Impact of chronic obstructive pulmonary disease on postoperative recurrence in patients with resected non-small-cell lung cancer.

Authors:  Guangliang Qiang; Chaoyang Liang; Fei Xiao; Qiduo Yu; Huanshun Wen; Zhiyi Song; Yanchu Tian; Bin Shi; Yongqing Guo; Deruo Liu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-12-29

9.  [Impact of Chronic Obstructive Pulmonary Disease on Risk of Recurrence in Patients with Resected Non-small Cell Lung Cancer].

Authors:  Guangliang Qiang; Qiduo Yu; Chaoyang Liang; Zhiyi Song; Bin Shi; Yongqing Guo; Deruo Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-03-20

Review 10.  Outcomes of lobectomy on pulmonary function for early stage non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD).

Authors:  Sen Wei; Feng Chen; Renwang Liu; Dianxun Fu; Yanye Wang; Bo Zhang; Dian Ren; Fan Ren; Zuoqing Song; Jun Chen; Song Xu
Journal:  Thorac Cancer       Date:  2020-05-06       Impact factor: 3.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.